EOS Technology Investment Syndicate

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Novosound Ltd is a company based in Edinburgh, United Kingdom, that specializes in manufacturing printable ultrasound sensors for various sectors, including aerospace, oil and gas, industrial, medical, veterinary, and dental applications. Founded in 2016, it emerged as the first spin-out from the University of the West of Scotland. Novosound employs innovative thin-film manufacturing techniques to overcome the limitations of traditional ultrasound technology, allowing for the development of highly customizable and scalable ultrasound solutions. The company's offerings include sensors, systems, and software designed to facilitate high-resolution imaging and measurement, particularly in non-destructive testing and medical fields.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

Provider of biotechnology genetics services intended to help clients focus on the global aquaculture supply chain. The company offers services like genotyping, pedigree reconstruction, gene expression, sex determination, triploidy validation, and more, enabling clients to meet the ever-expanding consumer demand for seafood.

Findie Development Limited, established in 2015 and based in London, United Kingdom, operates an online platform dedicated to discovering and streaming high-quality cinematic videos and short films from around the globe. The company curates a diverse collection of creative content, which is organized through a proprietary content engine that tailors recommendations to users based on their viewing preferences and interests. By bringing together a wide array of cinematic experiences in one accessible location, Findie aims to enhance the way audiences engage with film and video storytelling.

Digital Sports Arena (dba Gameday Live) is a BAFTA award winning team of game industry executives with a proven track record of delivering multi-million pound selling sports franchises. They have over a decade of experience in creating critically acclaimed and commercially successful sports management simulations. They set up Digital Sports Arena because they wanted to deliver a completely new gaming experience for fans of the genre. An experience which they think will change the landscape of sports simulation and head to head competition.